Document is current
Any future updates will be listed below
-
Authors
Fayad, Alicia
Principi, Iliana
Balestracci, Alejandro
Alconcher, Laura
Coccia, Paula
Adragna, Marta
Amoreo, Oscar
Bettendorff, María Carolina
Blumetti, María Valeria
Bonany, Pablo
Tonfi, María Laura Flores
Flynn, Luis
Ghezzi, Lidia
Montero, Jorge
Ramírez, Flavia
Seminara, Claudia
Suarez, Ángela
Spizzirri, Ana Paula
Rivas, Marta
Pichel, Mariana
Zylberman, Vanesa
Spatz, Linus
Massa, Carolina
Valerio, Marina
Sanguineti, Santiago
Colonna, Mariana
Roubicek, Ian
Goldbaum, Fernando https://orcid.org/0000-0001-6235-3002
,
-
Funding
Funding for this research was provided by:
INMUNOVA SA
- License Information
-
More Information
Article History
Received: 16 July 2024
Revised: 8 October 2024
Accepted: 18 October 2024
First Online: 12 November 2024
Declarations
:
: This trial was performed following the principles of the Declaration of Helsinki and Good Clinical Practice. The protocol was approved by the local Ethics Committees of each of the participating centers and the Argentine National Food and Drug Regulatory Agency (ANMAT) after approval by the Ethics Committee accredited by the corresponding Health Authority within the jurisdiction (Disposition Number: DI-2022–7068-APN-ANMAT#MS).
: AF, IP, AB, LA, PC, MA, OA, MCB, MVB, PB, MLFT, LF, LG, JM, FR, CS, AS, and APS declare reimbursement for conduction of clinical trial as investigator of the study. MR, MP, VZ, LS, CM, MV, SS, MC, IR, and FG report personal fees from Inmunova S.A.
